- Conditions
- COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
- Interventions
- RQ-001, Placebo
- Combination Product · Other
- Lead sponsor
- Red Queen Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Miami, Florida • Baltimore, Maryland + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1369–1392
of 13,796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 46
- States / cities
- Montgomery, Alabama • Long Beach, California • Los Angeles, California + 34 more
- Conditions
- Childhood Obesity, Overweight, Communication, Weight Loss
- Interventions
- Communication regarding overweight status, Risk-factor assessment and counseling, Lifestyle behavior assessment and counseling, Interval follow-up to readdress weight, Patient-centered communication
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Lung Transplant
- Interventions
- Off-pump lung transplantation, Venoarterial ECMO lung transplantation
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Atlanta, Georgia • Louisville, Kentucky + 6 more
- Conditions
- Type 2 Diabetes
- Interventions
- LY3502970, Dulaglutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 20
- States / cities
- Anaheim, California • Huntington Park, California • Los Angeles, California + 17 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Maraviroc
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • Wilmington, Delaware + 10 more
- Conditions
- Diabetic Foot Ulcers
- Interventions
- Total Contact Cast, Instant Total Contact Cast (ITCC), Removable Cast Walker (RCW)
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Dallas, Texas • Temple, Texas
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
- Interventions
- etanercept, methylprednisolone
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more
- Conditions
- Cholangiocarcinoma
- Interventions
- Nab-Paclitaxel and Gemcitabine
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 24
- States / cities
- Denver, Colorado • Chicago, Illinois • Oak Lawn, Illinois + 17 more
- Conditions
- Multiple Myeloma
- Interventions
- filgrastim, cisplatin, cyclophosphamide, dexamethasone, etoposide, thalidomide
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 93
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
- Conditions
- Post Partum Hemorrhage, Fibrinolysis; Hemorrhage, Blood Loss
- Interventions
- Tranexamic Acid, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Placebo, Veliparib, Carboplatin, Temozolomide, Paclitaxel
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 961 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 55 more
- Conditions
- Schizophrenia, Bipolar
- Interventions
- This is an observational study model that is family based
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 3,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2019
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Bronchospasm, Activity/Exercise Induced Bronchospasm
- Interventions
- Fluticasone propionate/salmeterol, Fluticasone Propionate
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 50
- States / cities
- Little Rock, Arkansas • Huntington Beach, California • Orange, California + 45 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Dalutrafusp alfa, mFOLFOX6 Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Dallas, Texas + 1 more
- Conditions
- High Risk Acute Myeloid Leukemia
- Interventions
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 31 more
- Conditions
- Ovarian Carcinoma
- Interventions
- Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
- Procedure · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 35 Years to 50 Years · Female only
- Enrollment
- 1,956 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2047
- U.S. locations
- 620
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 406 more
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-00734200 30 mg QD, PF-00734200 20 mg QD, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Litchfield Park, Arizona + 61 more
- Conditions
- Lung Cancer, Thoracic Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 87
- States / cities
- Irvine, California • Long Beach, California • Los Angeles, California + 77 more
- Conditions
- Covid19
- Interventions
- Apixaban 2.5 MG, Placebo
- Drug
- Lead sponsor
- Thomas L. Ortel
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 121
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 101 more
- Conditions
- Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
- Interventions
- Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more